Global Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: 2022-12-24
- Report ID: 143412
- Pages: 225
-
Format:
Short Description
Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells.
NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease.
The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity.
Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth.
Market Segmentation:
Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel.
On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies
On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.
On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others.
On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes
On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others.
Market Players
The key market players for natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 31
1.4 LIMITATIONS 33
1.5 MARKETS COVERED 34
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 DBMR TRIPOD DATA VALIDATION MODEL 39
2.6 MULTIVARIATE MODELLING 42
2.7 THERAPEUTICS LIFELINE CURVE 42
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.9 DBMR MARKET POSITION GRID 44
2.10 SECONDARY SOURCES 46
2.11 ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
3.1 EPIDEMIOLOGY 53
3.2 PESTEL ANALYSIS 54
3.3 PORTERS FIVE FORCES MODEL 55
3.4 INDUSTRIAL INSIGHTS: 56
3.5 PIPELINE ANALYSIS 58
4 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 59
5 MARKET OVERVIEW 61
5.1 DRIVERS 63
5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 63
5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 63
5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 64
5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 64
5.2 RESTRAINTS 65
5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 65
5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 65
5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 66
5.3 OPPORTUNITIES 67
5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 67
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 67
5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 68
5.4 CHALLENGES 68
5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 68
5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 69
5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 69
6 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 71
6.1 OVERVIEW 72
6.2 NK CELL THERAPIES 75
6.3 NK CELL DIRECTED ANTIBODIES 75
7 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 77
7.1 OVERVIEW 78
7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 81
7.3 BISPECIFIC ANTIBODIES 82
8 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 83
8.1 OVERVIEW 84
8.2 CANCER 87
8.2.1 SOLID TUMORS 88
8.2.2 HEMATOLOGIC MALIGNANCIES 88
8.2.2.1 MULTIPLE MYELOMA 89
8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 89
8.2.2.3 LYMPHOMA 89
8.2.2.4 OTHERS 89
8.2.3 OTHERS 89
8.3 IMMUNOPROLIFERATIVE DISORDERS 89
8.4 ACUTE INFECTIOUS DISEASES 90
8.5 GASTROINTESTINAL DISEASES 90
8.6 OTHERS 91
9 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 93
9.1 OVERVIEW 94
9.2 HOSPITALS 97
9.3 SPECIALTY CLINICS 97
9.4 RESEARCH & ACADEMIC INSTITUTES 98
10 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 100
10.1 OVERVIEW 101
10.2 HOSPITAL PHARMACIES 104
10.3 DIRECT TENDER 104
10.4 OTHERS 105
11 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 106
11.1 OVERVIEW 107
11.2 NORTH AMERICA 112
11.2.1 U.S. 119
11.2.2 CANADA 122
11.2.3 MEXICO 125
11.3 EUROPE 128
11.3.1 GERMANY 135
11.3.2 FRANCE 137
11.3.3 ITALY 139
11.3.4 U.K. 141
11.3.5 SPAIN 143
11.3.6 NETHERLANDS 145
11.3.7 RUSSIA 147
11.3.8 SWITZERLAND 149
11.3.9 TURKEY 151
11.3.10 AUSTRIA 153
11.3.11 NORWAY 155
11.3.12 HUNGARY 157
11.3.13 LITHUANIA 159
11.3.14 IRELAND 161
11.3.15 POLAND 163
11.3.16 LUXEMBOURG 165
11.3.17 REST OF EUROPE 167
11.4 ASIA-PACIFIC 168
11.4.1 JAPAN 175
11.4.2 CHINA 177
11.4.3 AUSTRALIA 179
11.4.4 SOUTH KOREA 181
11.4.5 INDIA 183
11.4.6 SINGAPORE 185
11.4.7 MALAYSIA 187
11.4.8 THAILAND 189
11.4.9 INDONESIA 191
11.4.10 PHILIPPINES 193
11.4.11 VIETNAM 195
11.4.12 REST OF ASIA-PACIFIC 197
11.5 SOUTH AMERICA 198
11.5.1 BRAZIL 204
11.5.2 ARGENTINA 206
11.5.3 PERU 208
11.5.4 REST OF SOUTH AMERICA 210
11.6 MIDDLE EAST & AFRICA 211
11.6.1 SAUDI ARABIA 218
11.6.2 SOUTH AFRICA 220
11.6.3 U.A.E 222
11.6.4 ISRAEL 224
11.6.5 KUWAIT 226
11.6.6 EGYPT 228
11.6.7 REST OF MIDDLE EAST & AFRICA 230
12 GLOBAL NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 231
12.1 COMPANY SHARE ANALYSIS: GLOBAL 231
13 SWOT ANALYSIS 232
14 COMPANY PROFILE 233
14.1 MERCK KGAA 233
14.1.1 COMPANY SNAPSHOT 233
14.1.2 RECENT FINANCIALS 233
14.1.3 PRODUCT PORTFOLIO 234
14.1.4 RECENT DEVELOPMENTS 234
14.2 BRISTOL-MYERS SQUIBB COMPANY 236
14.2.1 COMPANY SNAPSHOT 236
14.2.2 RECENT FINANCIALS 236
14.2.3 PRODUCT PORTFOLIO 237
14.2.4 RECENT DEVELOPMENTS 237
14.3 GLYCOSTEM 239
14.3.1 COMPANY SNAPSHOT 239
14.3.2 PRODUCT PORTFOLIO 239
14.3.3 RECENT DEVELOPMENTS 239
14.4 INNATE PHARMA, INC. 241
14.4.1 COMPANY SNAPSHOT 241
14.4.2 REVENUE ANALYSIS 241
14.4.3 PRODUCT PORTFOLIO 242
14.4.4 RECENT DEVELOPMENTS 242
14.5 REGENERON PHARMACEUTICALS INC. 244
14.5.1 COMPANY SNAPSHOT 244
14.5.2 RECENT FINANCIALS 244
14.5.3 PRODUCT PORTFOLIO 245
14.5.4 RECENT DEVELOPMENTS 245
14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 246
14.6.1 COMPANY SNAPSHOT 246
14.6.2 RECENT FINANCIALS 246
14.6.3 PRODUCT PORTFOLIO 247
14.6.4 RECENT DEVELOPMENTS 247
14.7 INMUNEBIO 248
14.7.1 COMPANY SNAPSHOT 248
14.7.2 REVENUE ANALYSIS 248
14.7.3 PRODUCT PORTFOLIO 249
14.7.4 RECENT DEVELOPMENTS 249
14.8 KIADIS PHARMA 251
14.8.1 COMPANY SNAPSHOT 251
14.8.2 REVENUE ANALYSIS 251
14.8.3 PRODUCT PORTFOLIO 252
14.8.4 RECENT DEVELOPMENTS 252
14.9 ACEPODIA INC. 254
14.9.1 COMPANY SNAPSHOT 254
14.9.2 PRODUCT PORTFOLIO 254
14.9.3 RECENT DEVELOPMENTS 254
14.10 AFFIMED GMBH 256
14.10.1 COMPANY SNAPSHOT 256
14.10.2 RECENT FINANCIALS 256
14.10.3 PRODUCT PORTFOLIO 257
14.10.4 RECENT DEVELOPMENTS 257
14.11 BIOHAVEN PHARMACEUTICALS 259
14.11.1 COMPANY SNAPSHOT 259
14.11.2 REVENUE ANALYSIS 259
14.11.3 PRODUCT PORTFOLIO 260
14.11.4 RECENT DEVELOPMENTS 260
14.12 BRINK BIOLOGICS, INC. 261
14.12.1 COMPANY SNAPSHOT 261
14.12.2 PRODUCT PORTFOLIO 261
14.12.3 RECENT DEVELOPMENT 261
14.13 CYTOVIA THERAPEUTICS 262
14.13.1 COMPANY SNAPSHOT 262
14.13.2 PRODUCT PORTFOLIO 262
14.13.3 RECENT DEVELOPMENTS 262
14.14 EMERCELL 264
14.14.1 COMPANY SNAPSHOT 264
14.14.2 PRODUCT PORTFOLIO 264
14.14.3 RECENT DEVELOPMENTS 264
14.15 FATE THERAPEUTICS 265
14.15.1 COMPANY SNAPSHOT 265
14.15.2 REVENUE ANALYSIS 265
14.15.3 PRODUCT PORTFOLIO 266
14.15.4 RECENT DEVELOPMENTS 266
14.16 GAMIDA CELL 268
14.16.1 COMPANY SNAPSHOT 268
14.16.2 PRODUCT PORTFOLIO 268
14.16.3 RECENT DEVELOPMENTS 269
14.17 ICELL GENE THERAPEUTICS 270
14.17.1 COMPANY SNAPSHOT 270
14.17.2 PRODUCT PORTFOLIO 270
14.17.3 RECENT DEVELOPMENT 270
14.18 IMMUNITYBIO, INC. 271
14.18.1 COMPANY SNAPSHOT 271
14.18.2 REVENUE ANALYSIS 271
14.18.3 PRODUCT PORTFOLIO 272
14.18.4 RECENT DEVELOPMENTS 272
14.19 MULTIMMUNE GMBH 273
14.19.1 COMPANY SNAPSHOT 273
14.19.2 PRODUCT PORTFOLIO 273
14.19.3 RECENT DEVELOPMENTS 273
14.20 NEKTAR 274
14.20.1 COMPANY SNAPSHOT 274
14.20.2 REVENUE ANALYSIS 274
14.20.3 PRODUCT PORTFOLIO 275
14.20.4 RECENT DEVELOPMENTS 275
14.21 NKARTA, INC. 276
14.21.1 COMPANY SNAPSHOT 276
14.21.2 PRODUCT PORTFOLIO 276
14.21.3 RECENT DEVELOPMENTS 276
14.22 PERSONGEN BIOTHERAPEUTICS 278
14.22.1 COMPANY SNAPSHOT 278
14.22.2 PRODUCT PORTFOLIO 278
14.22.3 RECENT DEVELOPMENTS 278
14.23 PHIO PHARMACEUTICALS 280
14.23.1 COMPANY SNAPSHOT 280
14.23.2 PRODUCT PORTFOLIO 280
14.23.3 RECENT DEVELOPMENTS 280
15 QUESTIONNAIRE 282
16 RELATED REPORTS 286
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
